REPACKAGED ORAL SOLID DRUG PRODUCTS EXPIRATION DATING

REPACKAGED ORAL SOLID DRUG PRODUCTS EXPIRATION DATING does not require additional stability testing if the equivalency of packaging materials has been established, a Center for Drug Evaluation and Research draft guideline on manufacturing and control requirements for repackaging states. The recently-issued guideline explains that a repacker may use the manufacturer's original expiration date without additional stability testing "if the drug product is repackaged into an equivalent container- closure system that is at least as protective or more protective than the original system." System equivalency, FDA explains, should extend to "any special protective materials, such as light transmission, seals or dessicants associated with the original container-closure system in which the drug product is marketed." Various methods may be used to establish the container-closure comparability, the guideline states, including referencing of studies performed by other firms. However, these studies "must directly pertain to the container-closure system used for the specific drug product in question, and documentation must be kept on file by the repackager." The repackaging guideline focuses on those areas of the current good manufacturing practice regulations (CGMPs) about which the agency most frequently has been questioned by firms engaged in repackaging operations. According to the guideline, repackers have expressed confusion about how the CGMPs apply depending on the type of repackaging operation, the specific dosage form being repackaged and the type of packaging materials involved. FDA investigators, in turn, have found significant GMP violations recently at a number of repackaging facilities. In several cases, extensive recalls and/or enforcement actions against the firms have resulted. Included in the CDER document is a discussion of specific requirements for expiration dating of products repackaged into unit-dose and unit-of-use containers. Along with stability studies and expiration dating, the guideline also addresses product testing/examination, labeling control, reserve samples and penicillin cross-contamination for repackaging operations. The regulatory requirements in these areas are discussed by CDER along with practices and procedures that may be used to comply with the regulations. The guideline applies only to the repackaging of solid oral dosage forms with approved NDAs or ANDAs. FDA requires premarket approval for repackaging of any other new drug dosage forms, including liquids, creams and ointments, even though the manufacturer holds an approved application. The repackaging guideline is part of an FDA effort to better regulate the downstream handling/manipulation of drug products. Earlier this year, FDA issued a "compliance policy guide" specifying parameters for acceptable pharmacy compounding within the new drug and GMP regulations ("The Pink Sheet" March 23, p. 8). FDA notes in the repackaging guideline that the CGMP requirements applicable to repackers do not apply to pharmacists filling prescriptions for identified patients. However, they do apply "to pharmacists, or any other entities that repackage drugs for distribution, which is beyond the regular practice of pharmacy, e.g., for resale or distribution to hospitals or other pharmacies." CDER is asking for industry input on the draft repackaging guideline. Comments should be submitted to FDA's Dockets Management Branch, 12420 Parklawn Dr., Rockville, Md. 20857 by Dec. 14.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Real-Time Release Of CRLs Is US FDA’s Goal, Agency Leaders Affirm

 

The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.

No Surprise Here: Foreign Drug Facilities Should Expect Surprise Inspections, US FDA Says

 
• By 

The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.

Base Benefit-Risk Decisions On Data, Not Opinion And Passion, CDER’s Tidmarsh Says

 
• By 

New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.